Literature DB >> 1779621

Agoraphobia in phenylketonuria.

S E Waisbren1, H L Levy.   

Abstract

We describe agoraphobia as a complication of phenylketonuria (PKU) in young adults. The five patients have classic PKU and received phenylalanine-restricted diet only in childhood. Only one has normal intelligence. All but one were also depressed. All were anxious. Three of the five had initiated the phenylalanine-restricted diet after 3 months of age. Two returned to the phenylalanine-restricted diet with dramatic reduction of symptoms. The frequency of manifestations of agoraphobia was also examined in 50 young women with PKU enrolled in a longitudinal study of psychosocial factors in maternal PKU, 47 of their acquaintances and 49 women with diabetes. All were administered a test of agoraphobic-avoidant behaviour. The women with PKU appeared to be more prone to social withdrawal and fear of leaving home. Twenty per cent were within the agoraphobia range of the Mobility Inventory. Those still on diet and those with non-PKU hyperphenylalaninaemia reported less avoidant behaviour than those who had terminated the diet in childhood. These results suggest that young adults with PKU are at risk for agoraphobia but that return to the phenylalanine-restricted diet may be an effective treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1779621     DOI: 10.1007/bf01799946

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  26 in total

Review 1.  Panic disorder: review of the empirical and rational basis of pharmacological treatment.

Authors:  G B Cassano; G Perugi; D M McNair
Journal:  Pharmacopsychiatry       Date:  1988-07       Impact factor: 5.788

2.  Late onset phenylalanine intoxication.

Authors:  L I Woolf
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

Review 3.  Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome.

Authors:  S E Waisbren; R R Schnell; H L Levy
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

4.  Serotonin function in panic disorders. The effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment.

Authors:  D S Charney; G R Heninger
Journal:  Arch Gen Psychiatry       Date:  1986-11

5.  Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria.

Authors:  N A Holtzman; R A Kronmal; W van Doorninck; C Azen; R Koch
Journal:  N Engl J Med       Date:  1986-03-06       Impact factor: 91.245

6.  Behavioural deviance in children with early treated phenylketonuria.

Authors:  J E Stevenson; J Hawcroft; M Lobascher; I Smith; O H Wolff; P J Graham
Journal:  Arch Dis Child       Date:  1979-01       Impact factor: 3.791

7.  A psychosocial model of a medical problem: Maternal phenylketonuria.

Authors:  S Shiloh; S E Waisbren; H L Levy
Journal:  J Prim Prev       Date:  1989-09

8.  Admissions of phenylketonuric patients to residential institutions before and after screening programs of the newborn infant.

Authors:  R A MacCready
Journal:  J Pediatr       Date:  1974-09       Impact factor: 4.406

9.  Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function.

Authors:  F Güttler; H Lou
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

10.  Psychosocial factors in maternal phenylketonuria: prevention of unplanned pregnancies.

Authors:  S E Waisbren; S Shiloh; P St James; H L Levy
Journal:  Am J Public Health       Date:  1991-03       Impact factor: 9.308

View more
  13 in total

1.  A randomized, placebo-controlled, double-blind trial of supplemental docosahexaenoic acid on cognitive processing speed and executive function in females of reproductive age with phenylketonuria: A pilot study.

Authors:  S H L Yi; J A Kable; M L Evatt; R H Singh
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-10-14       Impact factor: 4.006

2.  Outcomes of phenylketonuria with relevance to follow-up.

Authors:  F J van Spronsen; A Bélanger-Quintana
Journal:  JIMD Rep       Date:  2011-06-22

Review 3.  Psychiatric symptoms of inherited metabolic disease.

Authors:  Y Estrov; F Scaglia; O A Bodamer
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

4.  Maternal Phenylketonuria: Long-term Outcomes in Offspring and Post-pregnancy Maternal Characteristics.

Authors:  S E Waisbren; F Rohr; V Anastasoaie; M Brown; D Harris; A Ozonoff; S Petrides; A Wessel; H L Levy
Journal:  JIMD Rep       Date:  2015-02-25

5.  A cross-sectional study of docosahexaenoic acid status and cognitive outcomes in females of reproductive age with phenylketonuria.

Authors:  Sarah H L Yi; Julie A Kable; Marian L Evatt; Rani H Singh
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

6.  Adult psychosocial outcome in early-treated phenylketonuria.

Authors:  M D Ris; A M Weber; M M Hunt; H K Berry; S E Williams; N Leslie
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

Review 7.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

8.  Benefits of normalizing plasma phenylalanine: impact on behaviour and health. A case report.

Authors:  K Williams
Journal:  J Inherit Metab Dis       Date:  1998-12       Impact factor: 4.982

9.  Personality disorder in young women with treated phenylketonuria.

Authors:  S E Waisbren; J Zaff
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

10.  Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria.

Authors:  Alexandre Rebuffat; Cary O Harding; Zhaobing Ding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.